Table 1

Patients characteristicsa

A. Enrollment data
Entered (total)26
Entered and evaluated23
Median age (range) (yr)52 (25–76)
Sex (M/F)12/11
ECOG Performance Status
03
 114
 26
B. Tumor description and metastasis
Tumor typeNo. of patientsNo. of metastasisNo. of patients
Bladder1
Breast400
Cervix215
Gastrointestinal726
Larynx1≥315
Lung (non-small cell lung cancer)3
Prostate2
Head and neck1
Fallopian adenocarcinoma1
Fibrosarcoma1
Ewing’s sarcoma1
Thyroid carcinoma1
Liposarcoma1
C. Prior treatment
Chemotherapy25
(1 cycle 5 pts, 2 cycles 12 pts, 3 cycles 8 pts)
Mytomycin C/nitrosurea2
Immunotherapy5
Other (antihormone therapy)4
Radiation therapy20
D. Responding patients prior treatment
Principal diagnosisPrior study treatment
Gastroduodenal + hepatomegaliaSurgery and chemotherapy (2 cycles)
Thyroid carcinomaSurgery, chemotherapy (2 cycles), radiation
FibrosarcomaChemotherapy (1 cycle), immunotherapy
Larynx carcinomaSurgery, chemotherapy (1 cycle), radiation
Rectal carcinomaChemotherapy (3 cycles)
BreastSurgery, chemotherapy (2 cycles), radiation, and hormone therapy
  • a One patient with fibrosarcoma died on study day 3 for reasons unrelated to drug treatment. Another patient with gastrointestinal cancer presented a biliary obstruction and was removed from protocol on study day 6 for treatment. A patient with prostate cancer abandoned the protocol on study day 8, unable to adapt to the obligatory in-patient protocol conditions.